TransEnterix, Inc. (NYSEAMERICAN:TRXC)’s share price traded down 6.2% during mid-day trading on Monday . The stock traded as low as $1.17 and last traded at $1.22, 1,932,306 shares were traded during mid-day trading. A decline of 22% from the average session volume of 2,486,934 shares. The stock had previously closed at $1.30.
Several equities research analysts recently issued reports on the stock. Piper Jaffray Companies assumed coverage on shares of TransEnterix in a report on Wednesday, May 22nd. They issued a “neutral” rating and a $1.60 target price for the company. BTIG Research upgraded TransEnterix from a “neutral” rating to a “buy” rating and set a $3.00 price target for the company in a research note on Tuesday, May 14th. Finally, Zacks Investment Research downgraded TransEnterix from a “hold” rating to a “sell” rating in a research note on Saturday, July 13th.
TransEnterix (NYSEAMERICAN:TRXC) last posted its quarterly earnings results on Thursday, May 9th. The medical instruments supplier reported ($0.09) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.09). The business had revenue of $2.18 million during the quarter, compared to the consensus estimate of $4.50 million.
About TransEnterix (NYSEAMERICAN:TRXC)
TransEnterix, Inc, a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery. The company offers Senhance System, a multi-port robotic surgery system, which allows up to four arms to control robotic instruments and a camera in Europe.
Featured Article: Forex
Receive News & Ratings for TransEnterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransEnterix and related companies with MarketBeat.com's FREE daily email newsletter.